Compare AGX & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGX | TLX |
|---|---|---|
| Founded | 1961 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 2.2B |
| IPO Year | 1995 | N/A |
| Metric | AGX | TLX |
|---|---|---|
| Price | $570.94 | $9.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $409.50 | $21.13 |
| AVG Volume (30 Days) | ★ 481.9K | 250.6K |
| Earning Date | 03-26-2026 | 04-17-2026 |
| Dividend Yield | ★ 0.37% | N/A |
| EPS Growth | ★ 58.37 | N/A |
| EPS | ★ 9.74 | N/A |
| Revenue | ★ $944,606,000.00 | N/A |
| Revenue This Year | $28.94 | N/A |
| Revenue Next Year | $18.64 | N/A |
| P/E Ratio | ★ $55.44 | $150.33 |
| Revenue Growth | ★ 8.06 | N/A |
| 52 Week Low | $111.16 | $6.28 |
| 52 Week High | $588.00 | $19.93 |
| Indicator | AGX | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 64.90 | 63.49 |
| Support Level | $207.25 | $8.85 |
| Resistance Level | N/A | $9.92 |
| Average True Range (ATR) | 35.45 | 0.27 |
| MACD | 8.01 | 0.08 |
| Stochastic Oscillator | 89.11 | 80.87 |
Argan Inc is a United States-based construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC, and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Telecom Services, out of which Power Services derives the majority of revenue.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.